Featured Research

from universities, journals, and other organizations

New tool predicts survival in advanced prostate cancer

Date:
October 18, 2013
Source:
Duke Medicine
Summary:
Researchers have developed a tool for doctors to forecast the potential survival of individual patients, enabling faster, more accurate information on whether to try additional rounds of treatment or seek clinical trials.

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

But a good prognostic tool has been lacking in this setting, particularly since a new chemotherapy called cabazitaxel as been approved by the U.S. Food and Drug Administration as another line of treatment.

Now researchers at the Duke Cancer Institute have developed a tool for doctors to forecast the potential survival of individual patients, enabling faster, more accurate information on whether to try additional rounds of treatment or seek clinical trials.

The findings are published online in the Journal of the National Cancer Institute.

"Our findings provide a prognostic tool that relies on information that is routinely collected in clinical practice and should be readily available," said Susan Halabi, Ph.D., professor of biostatistics and bioinformatics at Duke and lead author of the study. "For patients with metastatic prostate cancer who are appropriate candidates for second-line chemotherapy, this model can be helpful for guiding care. It could also be used during clinical trials to assign patients in risk groups based on measurable criteria."

In their study, Halabi and colleagues developed and validated the new prognostic tool using two different clinical trials of prostate cancer patients whose cancer returned after they had undergone a regimen of docetaxel, the standard first-round chemotherapy that is used after hormone treatments have been ineffective.

The researcher's approach provides an understanding of the complex interactions between the host, the tumor factors and clinical outcomes.

By plugging in 17 variables -- including pain intensity, measurable disease, race, age, body mass index and others -- the researchers determined that certain key factors were relevant to overall survival.

Of the 17 variables, nine were determined to be predictive of survival: how a patient's physical performance is rated on a scale of 0-2; the length of time since the first chemotherapy ended; how extensive the disease is; whether the disease has spread to the liver, lungs or other organs; how much pain the patient is experiencing; the duration of hormone use; and levels of hemoglobin, prostate specific antigen and alkaline phosphatase.

Two of those factors had not previously been used in prognostic models -- the duration of hormone therapy and the amount of time since the first-round docetaxel treatment.

"Several new treatments have been developed in recent years that prolong life for men with metastatic prostate cancer," Halabi said. "As a result, it's increasingly important to provide a clear prognostic picture that can help guide both doctors and patients to the best options."

This tool is available online at https://www.cancer.duke.edu/Nomogram/secondlinechemotheray.html


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Halabi, C.-Y. Lin, E. J. Small, A. J. Armstrong, E. B. Kaplan, D. Petrylak, C. N. Sternberg, L. Shen, S. Oudard, J. de Bono, O. Sartor. Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. JNCI Journal of the National Cancer Institute, 2013; DOI: 10.1093/jnci/djt280

Cite This Page:

Duke Medicine. "New tool predicts survival in advanced prostate cancer." ScienceDaily. ScienceDaily, 18 October 2013. <www.sciencedaily.com/releases/2013/10/131018132000.htm>.
Duke Medicine. (2013, October 18). New tool predicts survival in advanced prostate cancer. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2013/10/131018132000.htm
Duke Medicine. "New tool predicts survival in advanced prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131018132000.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins